VeriTeQ Receives First Order for Its Q Inside Implantable Microchip from Partner Establishment Labs
VeriTeQ Receives First Order for Its Q Inside Implantable Microchip from Partner Establishment Labs d/b/a Motiva for September Delivery
Motiva Receives Order for Its Breast Implant with "Q Inside" from Customer in the European Union
DELRAY BEACH, Fla.--(BUSINESS WIRE)-- Digital Angel Corporation ("Digital Angel" or the "Company") (OTC Markets: DIGA), a provider of implantable medical device identification and radiation dose measurement technologies following its recent share exchange with VeriTeQ Acquisition Corporation ("VeriTeQ"), announced today that it has received its first order for its Q Inside implantable microchip for unique device identification ("UDI") from Establishment Labs, S.A. ("EL"), the Company's partner in the breast implant market, for September delivery. EL has received its first order from a customer in the European Union to offer the world's first traceable breast implant with "Q Inside" to patients. EL has filed for CE mark for its Motiva Implant Matrix® implants with "Q Inside" to be marketed in Europe.
VeriTeQ's "Q Inside," a passive radio frequency identification ("RFID") microchip, enables implantable medical devices to be quickly and safely identified from outside the body. Motiva Breast Implants® with "Q Inside" are designed to enable a manufacturer, physician or patient to access a secure online database and retrieve implant-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data. In September 2012, VeriTeQ entered into a development and supply agreement with EL, a global provider of breast implants under the Motiva Implant Matrix® brand name, to build next-generation breast implants that contain VeriTeQ's Unique Device Identifier ("UDI") called "Q Inside."
"We believe EL's agreement with a leading operator of plastic surgery centers in the EU to offer Motiva breast implants with 'Q Inside' provides significant validation for our technology and the market need to identify implantable medical devices from within the body," stated Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ.
About Digital Angel and VeriTeQ
Digital Angel, through its VeriTeQ wholly-owned subsidiary, develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
About EL
Establishment Labs S.A. is a privately held, global breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast implants (www.motivaimplants.com) for breast and body shaping implants.
Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All its products are produced in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.
Statements in this press release about our future expectations, including without limitation, the likelihood that Motiva's breast implants with Q Inside are designed to enable a manufacturer, physician or patient to access a secure online database and retrieve implant-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data; the likelihood that EL's agreement with a leading operator of plastic surgery centers in the EU to offer Motiva breast implants with Q Inside provides significant validation for VeriTeQ's technology and the market need to identify implantable medical devices from within the body; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the ability to promptly and effectively integrate the businesses of Digital Angel and VeriTeQ; VeriTeQ's ability to target the UDI sector and implantable medical device manufacturers; VeriTeQ's ability to raise capital; as well as other risks. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Digital Angel
Allison Tomek, 561-846-7003
atomek@veriteqcorp.com
KEYWORDS: United States Europe North America Florida
INDUSTRY KEYWORDS:
The article VeriTeQ Receives First Order for Its Q Inside Implantable Microchip from Partner Establishment Labs d/b/a Motiva for September Delivery originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
